NEW BRUNSWICK, N.J., Aug. 1 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today that Bayer CropScience has successfully completed the first R&D milestone related to Bayer's use of Senesco's technology in Brassica oilseeds.
Senesco's proprietary gene technology was licensed to Bayer CropScience in November 2006 to enhance Canola yields in Bayer's InVigor(R) canola hybrids and future hybrid's business internationally. Upon completion of this milestone, Senesco received an undisclosed payment from Bayer.
"We are pleased to arrive at this initial R&D milestone with Bayer CropScience," said Bruce Galton, President and CEO of Senesco. "We believe that our gene technology has broad application to both food and non-food crops."
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company,
headquartered in New Brunswick, NJ. Senesco has initiated preclinical
research to trigger or delay cell death in mammals (apoptosis) to determine
if the technology is applicable in human medicine. Accelerating apoptosis
may have applications to development of cancer treatments. Delaying
apoptosis may have applications to certain inflammatory and ischemic
diseases. Senesco takes its name from the scientific term for the aging of
plant cells: senescence. Delaying cell breakdown in plants extends
freshness after harvesting, while increasing crop yields, plant size and
resistance to environmental stress. The Company believes that its
technology can be used to develop superior strains of crops without any
modification other than delaying natural plant senescence. Senesco has
partnered with leading-edge companies engaged in agricultural biotechnology
|SOURCE Senesco Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved